EGFR and melanoma: Recently, four pre-clinical studies showed interesting combination profiles of EGFR inhibitors and inorganic arsenical-based drugs (sodium arsenite and arsenic trioxide) on melanomas [55], acute promyelocytic leukemia [56], hepatocellular carcinoma [57] and diverse solid cancer types including two osteosarcoma cell lines [58].